Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Crenolanib (ARO 002) 是一种口服生物可利用的 III 型酪氨酸激酶抑制剂,抑制 FLT3和 PDGFRα/β的 IC50分别为 4、11和 3.2 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 464 | 现货 | ||
5 mg | ¥ 698 | 现货 | ||
10 mg | ¥ 1,198 | 现货 | ||
25 mg | ¥ 1,997 | 现货 | ||
50 mg | ¥ 3,197 | 现货 | ||
100 mg | ¥ 4,280 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 777 | 现货 |
产品描述 | Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRα/β and FLT3 (IC50s: 11, 3.2, and 4 nM). |
靶点活性 | FLT3:0.74 nmol/L (Kd), PDGFRβ:2.1 nmol/L (Kd), PDGFRα:3.2 nmol/L (Kd) |
体外活性 | Crenolanib is a specific and potent inhibitor of RTK. The Kd of crenolanib for the wild-type receptors PDGFRA, PDGFRB, and FLT3 was 3.2, 2.1, and 0.74 nmol/L, respectively. In EOL-1 cell line, Crenolanib potently inhibits the kinase activity of the fusion oncogene with IC50 values of 21 nmol/L. In addition, it potently inhibits the proliferation of EOL-1 cells (IC50: 0.2 pmol/L) [1]. Crenolanib is a substrate of ABCB1, as evidenced by approximate five-fold resistance of ABCB1-overexpressing cells to crenolanib, reversal of this resistance by the ABCB1-specific inhibitor PSC-833 and stimulation of ABCB1 ATPase activity by crenolanib. In contrast, crenolanib was not a substrate of ABCG2 or ABCC1. Finally, incubation of the FLT3-ITD AML cell lines MV4-11 and MOLM-14 with crenolanib at a pharmacologically relevant concentration of 500 nM did not induce upregulation of ABCB1 cell surface expression [2]. Crenolanib treatment abolished phosphorylation of FLT3 and ERK in HB119 cells, as well as in the AML-patient–derived FLT3–ITD+ cell line Molm14. Fifty nanomolar crenolanib suppressed phosphorylation of FLT3 in primary isolates, including in leukemic blasts from a quizartinib-resistant patient whose disease had evolved an FLT3–ITD/D835Y mutation [3]. |
体内活性 | Crenolanib significantly inhibited the growth of tumor mass, and the strongest inhibitory effect was observed with 20 mg/kg treatment. Crenolanib induced massive apoptosis in tumor cells. Furthermore, the dosage of crenolanib applied was well tolerated by recipient mice. No weight loss was observed during the course of treatment [4]. Correlative data from an ongoing clinical trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo [5]. |
激酶实验 | Chinese hamster ovary (CHO) cells were transiently transfected with mutated KIT or PDGFRA cDNA constructs and treated with various concentrations of imatinib or crenolanib as previously described. Experiments involving recombinant DNA were carried out using biosafety level 2 conditions in accordance with published guidelines. Protein lysates from cell lines were prepared and subjected to immunoprecipitation using anti-KIT or anti-PDGFRA antibodies followed by sequential immunoblotting for phospho-KIT and total KIT, or phosphotyrosine or total PDGFRA, respectively, as previously reported. Densitometry was carried out to quantify drug effect using Photoshop 5.1 software, with the level of phospho-KIT or phospho-PDGFRA normalized to total protein. Densitometry and proliferation experimental results were analyzed using Calcusyn 2.1 software to mathematically determine the IC50 values. The Wilcoxon rank sum test was used to compare the IC50 values of imatinib and crenolanib for a given mutation [1]. |
细胞实验 | Cells were added to 96-well plates at densities of 20,000 cells per well and incubated with imatinib or crenolanib for 72 hours before measuring cellular proliferation using a 2,3-bis[2-methoxyl-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT)–based assay [1]. |
动物实验 | A549 cells were injected into the axillary regions of mice (2×10^6 cells/mouse). When the tumor volumes reached 70 mm^3, the mice were randomly allocated to the control group, low-dose crenolanib group (10 mg/kg), or high-dose crenolanib group (20 mg/kg) (n=6 per group). The vehicle for crenolanib treatment consists of 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300. The tumor size and mouse body weight were measured every other day for about 2 weeks. The tumor volume was calculated as follows: (mm^3) = (width × width × length)/2. After treatment, the mice were euthanized using carbon dioxide, and the tumors were harvested and analyzed [4]. |
别名 | ARO 002, CP-868596 |
化合物与蛋白结合的复合物 |
Crystal Structure of the Human CAMKK2B in complex with Crenolanib |
分子量 | 443.54 |
分子式 | C26H29N5O2 |
CAS No. | 670220-88-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 89 mg/mL (200.65 mM), Heating is recommended.
Ethanol: 7 mg/mL (15.78 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.2546 mL | 11.2729 mL | 22.5459 mL | 56.3647 mL |
5 mM | 0.4509 mL | 2.2546 mL | 4.5092 mL | 11.2729 mL | |
10 mM | 0.2255 mL | 1.1273 mL | 2.2546 mL | 5.6365 mL | |
DMSO | 20 mM | 0.1127 mL | 0.5636 mL | 1.1273 mL | 2.8182 mL |
50 mM | 0.0451 mL | 0.2255 mL | 0.4509 mL | 1.1273 mL | |
100 mM | 0.0225 mL | 0.1127 mL | 0.2255 mL | 0.5636 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Crenolanib 670220-88-9 Angiogenesis Autophagy Tyrosine Kinase/Adaptors FLT PDGFR Inhibitor FLT3 Platelet-derived growth factor receptor CD135 ARO002 ARO 002 CP868596 CP 868596 Cluster of differentiation antigen 135 CP-868596 inhibit Fms like tyrosine kinase 3 ARO-002 inhibitor